1
|
Hurcombe JA, Lay AC, Ni L, Barrington AF, Woodgett JR, Quaggin SE, Welsh GI, Coward RJ. Podocyte GSK3α is important for autophagy and its loss detrimental for glomerular function. FASEB Bioadv 2019; 1:498-510. [PMID: 31825015 PMCID: PMC6902909 DOI: 10.1096/fba.2019-00011] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Podocytes are key cells in maintaining the integrity of the glomerular filtration barrier and preventing albuminuria. Glycogen synthase kinase 3 (GSK3) is a multi-functional serine/threonine kinase existing as two distinct but related isoforms (α and β). In the podocyte it has previously been reported that inhibition of the β isoform is beneficial in attenuating a variety of glomerular disease models but loss of both isoforms is catastrophic. However, it is not known what the role of GSK3α is in these cells. We now show that GSK3α is present and dynamically modulated in podocytes. When GSK3α is transgenically knocked down specifically in the podocytes of mice it causes mild but significant albuminuria by 6-weeks of life. Its loss also does not protect in models of diabetic or Adriamycin-induced nephropathy. In vitro deletion of podocyte GSK3α causes cell death and impaired autophagic flux suggesting it is important for this key cellular process. Collectively this work shows that GSK3α is important for podocyte health and that augmenting its function may be beneficial in treating glomerular disease.
Collapse
Affiliation(s)
| | - A C Lay
- Bristol Renal, University of Bristol
| | - L Ni
- Bristol Renal, University of Bristol
| | | | - J R Woodgett
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System & University of Toronto, Canada
| | - S E Quaggin
- Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois, US
| | - G I Welsh
- Bristol Renal, University of Bristol
| | | |
Collapse
|
2
|
Hurcombe JA, Hartley P, Lay AC, Ni L, Bedford JJ, Leader JP, Singh S, Murphy A, Scudamore CL, Marquez E, Barrington AF, Pinto V, Marchetti M, Wong LF, Uney J, Saleem MA, Mathieson PW, Patel S, Walker RJ, Woodgett JR, Quaggin SE, Welsh GI, Coward RJM. Podocyte GSK3 is an evolutionarily conserved critical regulator of kidney function. Nat Commun 2019; 10:403. [PMID: 30679422 PMCID: PMC6345761 DOI: 10.1038/s41467-018-08235-1] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2018] [Accepted: 12/21/2018] [Indexed: 01/18/2023] Open
Abstract
Albuminuria affects millions of people, and is an independent risk factor for kidney failure, cardiovascular morbidity and death. The key cell that prevents albuminuria is the terminally differentiated glomerular podocyte. Here we report the evolutionary importance of the enzyme Glycogen Synthase Kinase 3 (GSK3) for maintaining podocyte function in mice and the equivalent nephrocyte cell in Drosophila. Developmental deletion of both GSK3 isoforms (α and β) in murine podocytes causes late neonatal death associated with massive albuminuria and renal failure. Similarly, silencing GSK3 in nephrocytes is developmentally lethal for this cell. Mature genetic or pharmacological podocyte/nephrocyte GSK3 inhibition is also detrimental; producing albuminuric kidney disease in mice and nephrocyte depletion in Drosophila. Mechanistically, GSK3 loss causes differentiated podocytes to re-enter the cell cycle and undergo mitotic catastrophe, modulated via the Hippo pathway but independent of Wnt-β-catenin. This work clearly identifies GSK3 as a critical regulator of podocyte and hence kidney function.
Collapse
Affiliation(s)
- J A Hurcombe
- Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
| | - P Hartley
- Bournemouth University, Bournemouth, BH12 5BB, UK
| | - A C Lay
- Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
| | - L Ni
- Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
| | - J J Bedford
- Dunedin School of Medicine, University of Otago, Dunedin, 9016, New Zealand
| | - J P Leader
- Dunedin School of Medicine, University of Otago, Dunedin, 9016, New Zealand
| | - S Singh
- Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
| | - A Murphy
- Department of Pathology, Southern General Hospital, Glasgow, G51 4TF, UK
| | - C L Scudamore
- Mary Lyon Centre, MRC Harwell, Didcot, Oxford, OX11 0RD, UK
| | - E Marquez
- Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
| | - A F Barrington
- Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
| | - V Pinto
- Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
| | - M Marchetti
- Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
| | - L-F Wong
- Translational Health Sciences, University of Bristol, Bristol, BS2 8DZ, UK
| | - J Uney
- Translational Health Sciences, University of Bristol, Bristol, BS2 8DZ, UK
| | - M A Saleem
- Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
| | - P W Mathieson
- Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
- The University of Hong Kong, Pokfulam, Hong Kong
| | - S Patel
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System & University of Toronto, Toronto, M5G 1X5, Canada
- Institute of Metabolic Science, University of Cambridge, Cambridge, CB2 0QQ, UK
| | - R J Walker
- Dunedin School of Medicine, University of Otago, Dunedin, 9016, New Zealand
| | - J R Woodgett
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System & University of Toronto, Toronto, M5G 1X5, Canada
| | - S E Quaggin
- Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, 60611, IL, USA
| | - G I Welsh
- Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
| | - R J M Coward
- Bristol Renal, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK.
| |
Collapse
|
3
|
Hale LJ, Welsh GI, Perks CM, Hurcombe JA, Moore S, Hers I, Saleem MA, Mathieson PW, Murphy AJ, Jeansson M, Holly JM, Hardouin SN, Coward RJ. Insulin-like growth factor-II is produced by, signals to and is an important survival factor for the mature podocyte in man and mouse. J Pathol 2013; 230:95-106. [PMID: 23299523 DOI: 10.1002/path.4165] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2012] [Revised: 12/03/2012] [Accepted: 12/26/2012] [Indexed: 01/10/2023]
Abstract
Podocytes are crucial for preventing the passage of albumin into the urine and, when lost, are associated with the development of albuminuria, renal failure and cardiovascular disease. Podocytes have limited capacity to regenerate, therefore pro-survival mechanisms are critically important. Insulin-like growth factor-II (IGF-II) is a potent survival and growth factor; however, its major function is thought to be in prenatal development, when circulating levels are high. IGF-II has only previously been reported to continue to be expressed in discrete regions of the brain into adulthood in rodents, with systemic levels being undetectable. Using conditionally immortalized human and ex vivo adult mouse cells of the glomerulus, we demonstrated the podocyte to be the major glomerular source and target of IGF-II; it signals to this cell via the IGF-I receptor via the PI3 kinase and MAPK pathways. Functionally, a reduction in IGF signalling causes podocyte cell death in vitro and glomerular disease in vivo in an aged IGF-II transgenic mouse that produces approximately 60% of IGF-II due to a lack of the P2 promoter of this gene. Collectively, this work reveals the fundamental importance of IGF-II in the mature podocyte for glomerular health across mammalian species.
Collapse
Affiliation(s)
- L J Hale
- Academic and Children's Renal Unit, University of Bristol, Learning and Research, Southmead Hospital, Bristol, BS10 5NB, UK
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|